Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftibuten is an orally administered, third-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It is effective against pathogens such as *Haemophilus influenzae*, *Moraxella catarrhalis*, and certain strains of *Streptococcus pneumoniae* and *Streptococcus pyogenes*. Ceftibuten works by binding to penicillin-binding proteins (PBPs) in bacteria, inhibiting cell wall synthesis and leading to bacterial cell death. It is indicated for acute bacterial exacerbations of chronic bronchitis, acute otitis media, pharyngitis, tonsillitis, pneumonia, urinary tract infections, enteritis, and gastroenteritis[1][2][4][5][7]. The drug demonstrates high stability against many beta-lactamases but may be less effective against organisms with chromosomally-mediated resistance mechanisms[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftibuten.